The FDA has approved rezafungin (Rezzayo – Cidara/Melinta), an intravenous echinocandin antifungal, for once-weekly treatment of candidemia and invasive candidiasis (IC) in adults with limited or no alternative options. It is the first new drug to become available in the US in more than 15 years for treatment of systemic Candida infections.
No takes yet. Share an insight, caveat, or question.
A 2024 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: